{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:19:37Z","timestamp":1782245977543,"version":"3.54.5"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T00:00:00Z","timestamp":1665360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Two new classes of hybrid quinoline\u2013imidazole\/benzimidazole derivatives (the hybrid <jats:bold>QIBS<\/jats:bold> salts and <jats:bold>QIBC<\/jats:bold> cycloadducts) were designed and synthesized to evaluate their anticancer and antimicrobial activity. The strategy adopted for synthesis is straight and efficient, in four steps: <jats:italic>N<\/jats:italic>-acylation, <jats:italic>N<\/jats:italic>-alkylation, quaternization and a Huisgen 3\u2009+\u20092 cycloaddition. The in vitro single-dose anticancer assay of forty six hybrid quinoline-benzimidazole compounds reveal that one <jats:bold>QIBS<\/jats:bold> salt (<jats:bold>11h<\/jats:bold>), has an excellent quasi nonselective activity against all type of cancer cell with an excellent PGI in the area of 90\u2013100% and very good lethality. Three others quinoline\u2013imidazole\/benzimidazole hybrids (<jats:bold>8h<\/jats:bold>, <jats:bold>12h<\/jats:bold>, <jats:bold>12f<\/jats:bold>) has an excellent selective activity against some cancer cell lines: breast cancer MDA-MB-468 and Leukemia HL-60\u00a0TB). The five-dose assay screening confirms that compound <jats:bold>11h<\/jats:bold> possesses excellent anti-proliferative activity, with GI<jats:sub>50<\/jats:sub> in the range of <jats:italic>nano<\/jats:italic>-molar, against some cancer cell lines: Leukemia HL-60\u00a0TB, Leukemia K-526, Leukemia RPMI-8226, Breast cancer MDA-MB-468, Lung cancer HOP-92 and Ovarian cancer IGROV1. The antibacterial assay indicates that three hybrid <jats:bold>QIBS<\/jats:bold> salts (<jats:bold>12f<\/jats:bold>, <jats:bold>12c<\/jats:bold>, <jats:bold>12d<\/jats:bold>) have an excellent activity against Gram-negative bacteria <jats:italic>E. coli<\/jats:italic> (superior to control Gentamicin) while against Gram-positive bacteria <jats:italic>S. aureus<\/jats:italic> only one compound <jats:bold>8i<\/jats:bold> (R<jats:sub>2<\/jats:sub>\u2009=\u2009-CF3) exhibits a significant activity (superior to control Gentamicin). The MIC assay indicates that two other compounds (<jats:bold>11h<\/jats:bold>, <jats:bold>12h<\/jats:bold>) are biologically active to a very low concentration, in the range of <jats:italic>nano<\/jats:italic>-molar. We believe that all these excellent assets related to anticancer and antibacterial activities, make from our hybrid quinoline\u2013imidazole\/benzimidazole compounds bearing a phenyl group (R<jats:sub>2<\/jats:sub>\u2009=\u2009\u2013C<jats:sub>6<\/jats:sub>H<jats:sub>5<\/jats:sub>) in the <jats:italic>para<\/jats:italic> (4)-position of the benzoyl moiety a good candidate for future drug developing.\n<\/jats:p>","DOI":"10.1038\/s41598-022-21435-6","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T15:05:33Z","timestamp":1665414333000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Quinoline\u2013imidazole\/benzimidazole derivatives as dual-\/multi-targeting hybrids inhibitors with anticancer and antimicrobial activity"],"prefix":"10.1038","volume":"12","author":[{"given":"Dumitrela","family":"Diaconu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilichia","family":"Antoci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Mangalagiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorina","family":"Amariucai-Mantu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ionel I.","family":"Mangalagiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,10]]},"reference":[{"key":"21435_CR1","unstructured":"WHO. Cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cancer. Accessed 5 Feb 2022."},{"key":"21435_CR2","doi-asserted-by":"publisher","first-page":"10257","DOI":"10.1021\/jm501100b","volume":"57","author":"E Vitaku","year":"2014","unstructured":"Vitaku, E., Smith, D. T. & Njardarson, J. T. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals. J. Med. Chem. 57, 10257\u201310274. https:\/\/doi.org\/10.1021\/jm501100b (2014).","journal-title":"J. Med. Chem."},{"key":"21435_CR3","doi-asserted-by":"publisher","first-page":"28313","DOI":"10.1039\/C6RA24662A","volume":"7","author":"V Abbot","year":"2017","unstructured":"Abbot, V. et al. Small hybrid heteroaromatics: Resourceful biological tools in cancer research. RSC Adv. 7, 28313\u201328349. https:\/\/doi.org\/10.1039\/C6RA24662A (2017).","journal-title":"RSC Adv."},{"key":"21435_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ejmech.2016.09.023","volume":"125","author":"J Akhtar","year":"2017","unstructured":"Akhtar, J. et al. Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities. Eur. J. Med. Chem. 125, 143\u2013189. https:\/\/doi.org\/10.1016\/j.ejmech.2016.09.023 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ejmech.2014.03.018","volume":"77","author":"K Nepali","year":"2014","unstructured":"Nepali, K. et al. Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids. Eur. J. Med. Chem. 77, 422\u2013487. https:\/\/doi.org\/10.1016\/j.ejmech.2014.03.018 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR6","unstructured":"WHO. Global Strategy for Containment of Antimicrobial Resistance. https:\/\/www.who.int\/drugresistance\/WHO_Global_Strategy_English.pdf. Accessed 5 Feb 2022."},{"key":"21435_CR7","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jiph.2016.08.007","volume":"10","author":"M Frieri","year":"2017","unstructured":"Frieri, M., Kumar, K. & Boutin, A. Antibiotic resistance. J. Infect. Public. Heal. 10, 369\u2013378. https:\/\/doi.org\/10.1016\/j.jiph.2016.08.007 (2017).","journal-title":"J. Infect. Public. Heal."},{"key":"21435_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3109\/1040841X.2014.974500","volume":"42","author":"ME Rodrigues","year":"2016","unstructured":"Rodrigues, M. E., Silva, S., Azeredo, J. & Henriques, M. Novel strategies to fight Candida species infection. Crit. Rev. Microbiol. 42, 594\u2013606. https:\/\/doi.org\/10.3109\/1040841X.2014.974500 (2016).","journal-title":"Crit. Rev. Microbiol."},{"key":"21435_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2020.115973","volume":"32","author":"BS Matada","year":"2021","unstructured":"Matada, B. S., Pattanashettar, R. & Yernale, N. G. A comprehensive review on the biological interest of quinoline and its derivatives. Bioorg. Med. Chem. 32, 115973. https:\/\/doi.org\/10.1016\/j.bmc.2020.115973 (2021).","journal-title":"Bioorg. Med. Chem."},{"key":"21435_CR10","doi-asserted-by":"publisher","first-page":"653","DOI":"10.2174\/1570193X16666190213105146","volume":"16","author":"LS Kumari","year":"2019","unstructured":"Kumari, L. S., Mazumder, A., Kumar, V. & Gupta, S. Synthesis and biological potentials of quinoline analogues: A review of literature. Mini Rev. Org. Chem. 16, 653\u2013688. https:\/\/doi.org\/10.2174\/1570193X16666190213105146 (2019).","journal-title":"Mini Rev. Org. Chem."},{"key":"21435_CR11","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.ejmech.2016.12.010","volume":"126","author":"W Akhtar","year":"2017","unstructured":"Akhtar, W. et al. Therapeutic evolution of benzimidazole derivatives in the last quinquennial period. Eur. J. Med. Chem. 126, 705\u2013753. https:\/\/doi.org\/10.1016\/j.ejmech.2016.12.010 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR12","doi-asserted-by":"publisher","first-page":"S157","DOI":"10.1016\/j.arabjc.2012.07.017","volume":"10","author":"MS Salahuddin","year":"2017","unstructured":"Salahuddin, M. S. & Mazumder, A. Benzimidazoles: A biologically active compounds. Arab. J. Chem. 10, S157\u2013S173. https:\/\/doi.org\/10.1016\/j.arabjc.2012.07.017 (2017).","journal-title":"Arab. J. Chem."},{"key":"21435_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.2174\/1570163816666190320123340","volume":"17","author":"P Chopra","year":"2020","unstructured":"Chopra, P. & Sahu, J. Biological significance of imidazole-based analogues in new drug development. Curr. Drug. Discov. Technol. 17, 574\u2013584. https:\/\/doi.org\/10.2174\/1570163816666190320123340 (2020).","journal-title":"Curr. Drug. Discov. Technol."},{"key":"21435_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113555","volume":"220","author":"A Lauria","year":"2021","unstructured":"Lauria, A., La Monica, G., Bono, A. & Martorana, A. Quinoline anticancer agents active on DNA and DNA-interacting proteins: From classical to emerging therapeutic targets. Eur. J. Med. Chem. 220, 113555. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113555 (2021).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ejmech.2019.01.017","volume":"165","author":"F Gao","year":"2019","unstructured":"Gao, F., Zhang, X., Wang, T. & Xiao, J. Quinolone hybrids and their anticancer activities: An overview. Eur. J. Med. Chem. 165, 59\u201379. https:\/\/doi.org\/10.1016\/j.ejmech.2019.01.017 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmech.2019.04.033","volume":"174","author":"J Zhang","year":"2019","unstructured":"Zhang, J., Wang, S., Ba, Y. & Xu, Z. 1,2,4-Triazole-quinoline\/quinolone hybrids as potential antibacterial agents. Eur. J. Med. Chem. 174, 1\u20138. https:\/\/doi.org\/10.1016\/j.ejmech.2019.04.033 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR17","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejmech.2017.07.061","volume":"139","author":"YQ Hu","year":"2017","unstructured":"Hu, Y. Q. et al. Quinoline hybrids and their antiplasmodial and antimalarial activities. Eur. J. Med. Chem. 139, 22\u201347. https:\/\/doi.org\/10.1016\/j.ejmech.2017.07.061 (2017).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.tube.2014.04.001","volume":"94","author":"AK Kakkar","year":"2014","unstructured":"Kakkar, A. K. & Dahiya, N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis 94, 357\u2013362. https:\/\/doi.org\/10.1016\/j.tube.2014.04.001 (2014).","journal-title":"Tuberculosis"},{"key":"21435_CR19","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ejmech.2014.01.030","volume":"76","author":"M Gaba","year":"2014","unstructured":"Gaba, M. & Singh, S. Benzimidazole: An emerging scaffold for analgesic and anti- inflammatory agents. Eur. J. Med. Chem. 76, 494\u2013505. https:\/\/doi.org\/10.1016\/j.ejmech.2014.01.030 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR20","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ejmech.2019.02.008","volume":"167","author":"Y Fang","year":"2019","unstructured":"Fang, Y., Zhou, H., Gu, Q. & Xu, J. Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer\u2019s disease. Eur. J. Med. Chem. 167, 133\u2013145. https:\/\/doi.org\/10.1016\/j.ejmech.2019.02.008 (2019).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR21","doi-asserted-by":"publisher","first-page":"38297","DOI":"10.1039\/D1RA07484A","volume":"11","author":"D Diaconu","year":"2021","unstructured":"Diaconu, D. et al. Ultrasound assisted synthesis of hybrid quinoline-imidazole derivatives: a green synthetic approach. RSC Adv. 11, 38297\u201338301. https:\/\/doi.org\/10.1039\/D1RA07484A (2021).","journal-title":"RSC Adv."},{"key":"21435_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4155\/fmc-2019-0063","volume":"12","author":"V Antoci","year":"2020","unstructured":"Antoci, V. et al. Bis-(imidazole\/benzimidazole)-pyridine derivatives: Synthesis, structure and antimycobacterial activity: Part XII. Future Med. Chem. 12, 207\u2013222. https:\/\/doi.org\/10.4155\/fmc-2019-0063 (2020).","journal-title":"Future Med. Chem."},{"key":"21435_CR23","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.3390\/molecules25122946","volume":"25","author":"D Diaconu","year":"2020","unstructured":"Diaconu, D. et al. Hybrid quinoline-sulfonamide complexes (M2+) derivatives with antimicrobial activity. Molecules 25, 2946. https:\/\/doi.org\/10.3390\/molecules25122946 (2020).","journal-title":"Molecules"},{"key":"21435_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.2174\/0929867326666181220094229","volume":"27","author":"CN Lungu","year":"2020","unstructured":"Lungu, C. N. et al. Hybrid imidazole: Pyridine derivatives: computational approach to novel anticancer DNA intercalators. Curr. Med. Chem. 27, 154\u2013169. https:\/\/doi.org\/10.2174\/0929867326666181220094229 (2020).","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"21435_CR25","doi-asserted-by":"publisher","first-page":"67","DOI":"10.24193\/subbchem.2019.3.06","volume":"64","author":"C Al Matarneh","year":"2019","unstructured":"Al Matarneh, C. et al. Synthesis and antibacterial evaluation of new pyrrolo[3\u2019,4\u2019:3,4]pyrrolo[1,2-a]quinoline and pyrrolo[3\u2019,4\u2019:3,4] pyrrolo[1,2-a]isoquinoline derivatives. Stud. UBB Chem. 64(3), 67\u201380 (2019).","journal-title":"Stud. UBB Chem."},{"key":"21435_CR26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/14756366.2016.1190711","volume":"31","author":"D Mantu","year":"2016","unstructured":"Mantu, D. et al. Hybrid imidazole (benzimidazole)\/pyridine (quinoline) derivatives and evaluation of their anticancer and antimycobacterial activity. J. Enzyme Inhib. Med. Chem. 31, 96\u2013103. https:\/\/doi.org\/10.1080\/14756366.2016.1190711 (2016).","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"21435_CR27","doi-asserted-by":"publisher","first-page":"10187","DOI":"10.1002\/slct.202002790","volume":"5","author":"P Panda","year":"2020","unstructured":"Panda, P. & Chakroborty, S. Navigating the synthesis of quinoline hybrid molecules as promising anticancer agents. Chem. Sel. 5, 10187\u201310199. https:\/\/doi.org\/10.1002\/slct.202002790 (2020).","journal-title":"Chem. Sel."},{"key":"21435_CR28","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"143","author":"NM Raghavendra","year":"2018","unstructured":"Raghavendra, N. M. et al. Dual or multi-targeting inhibitors: The next generation anticancer agents. Eur. J. Med. Chem. 143, 1277\u20131300. https:\/\/doi.org\/10.1016\/j.ejmech.2017.10.021 (2018).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.ejmech.2017.10.021","volume":"24","author":"A Rana","year":"2015","unstructured":"Rana, A. et al. A review on pharmacophoric designs of antiproliferative agents. Med. Chem. Res. 24, 903\u2013920. https:\/\/doi.org\/10.1016\/j.ejmech.2017.10.021 (2015).","journal-title":"Med. Chem. Res."},{"key":"21435_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejmech.2014.01.060","volume":"76","author":"Y Bansal","year":"2014","unstructured":"Bansal, Y. & Silakari, O. Multifunctional compounds: Smart molecules for multifactorial diseases. Eur. J. Med. Chem. 76, 31\u201342. https:\/\/doi.org\/10.1016\/j.ejmech.2014.01.060 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR31","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ejmech.2014.01.018","volume":"76","author":"CB Sangani","year":"2014","unstructured":"Sangani, C. B. et al. Design, synthesis and molecular modeling of pyrazole-quinoline-pyridine hybrids as a new class of antimicrobial and anticancer agents. Eur. J. Med. Chem. 76, 549\u2013557. https:\/\/doi.org\/10.1016\/j.ejmech.2014.01.018 (2014).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR32","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.2174\/092986707780831168","volume":"14","author":"JB Bremner","year":"2007","unstructured":"Bremner, J. B., Ambrus, J. I. & Samosorn, S. Dual action-based approaches to antibacterial agents. Curr. Med. Chem. 14, 1459\u20131477. https:\/\/doi.org\/10.2174\/092986707780831168 (2007).","journal-title":"Curr. Med. Chem."},{"key":"21435_CR33","doi-asserted-by":"publisher","first-page":"8587","DOI":"10.1016\/j.bmc.2008.08.016","volume":"16","author":"D Castagnolo","year":"2008","unstructured":"Castagnolo, D. et al. Synthesis, biological evaluation and SAR study of novel pyrazole analogues as inhibitors of Mycobacterium tuberculosis. Bioorg. Med. Chem. 16, 8587\u20138591. https:\/\/doi.org\/10.1016\/j.bmc.2008.08.016 (2008).","journal-title":"Bioorg. Med. Chem."},{"key":"21435_CR34","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2174\/1570180811666140819223501","volume":"12","author":"R Danac","year":"2015","unstructured":"Danac, R., Daniloaia, T., Antoci, V. & Mangalagiu, I. I. Design, synthesis and antimycobacterial activity of some new azaheterocycles: Phenanthroline with p-halogeno-benzoyl skeleton: Part V. Lett. Drug Des. Discov. 12, 14\u201319 (2015).","journal-title":"Lett. Drug Des. Discov."},{"key":"21435_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.3390\/ph14040335","volume":"14","author":"V Antoci","year":"2021","unstructured":"Antoci, V. et al. Benzoquinoline derivatives: A straightforward and efficient route to antibacterial and antifungal agents. Pharmaceuticals 14, 335. https:\/\/doi.org\/10.3390\/ph14040335 (2021).","journal-title":"Pharmaceuticals"},{"key":"21435_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112651","volume":"204","author":"H Hu","year":"2020","unstructured":"Hu, H. et al. Discovery of novel c-nesenchymal-epithelia transition factor and histone deacetylase dual inhibitors. Eur. J. Med. Chem. 204, 112651. https:\/\/doi.org\/10.1016\/j.ejmech.2020.112651 (2020).","journal-title":"Eur. J. Med. Chem."},{"key":"21435_CR37","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/zaac.200390041","volume":"629","author":"B Mac\u0131as","year":"2003","unstructured":"Mac\u0131as, B. et al. Synthesis and structural characterization of zinc complexes with sulfonamides containing 8-aminoquinoleine. Z. Anorg. Allg. Chem. 629, 255\u2013260 (2003).","journal-title":"Z. Anorg. Allg. Chem."},{"key":"21435_CR38","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"HR Shoemaker","year":"2006","unstructured":"Shoemaker, H. R. The NCI60 human tumour cell line anticancer drug screen. Nat. Rev. Cancer 6, 813\u2013823. https:\/\/doi.org\/10.1038\/nrc1951 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"21435_CR39","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jnci\/82.13.1107","volume":"82","author":"P Skehan","year":"1990","unstructured":"Skehan, P. et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107\u20131112. https:\/\/doi.org\/10.1093\/jnci\/82.13.1107 (1990).","journal-title":"J. Natl. Cancer Inst."},{"key":"21435_CR40","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-1-4615-8152-9_2","volume-title":"Anticancer Drug Development Guide: Cancer Drug Discovery and Development","author":"RB Boyd","year":"1997","unstructured":"Boyd, R. B. The NCI in vitro anticancer drug discovery screen. In Anticancer Drug Development Guide: Cancer Drug Discovery and Development (ed. Teicher, B. A.) 23\u201342 (Humana Press, 1997). https:\/\/doi.org\/10.1007\/978-1-4615-8152-9_2."},{"key":"21435_CR41","unstructured":"Weinstein, M. P. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 11th Edition, CLSI document M07-A11. (Clinical and Laboratory Standards Institute, 2018). https:\/\/clsi.org\/media\/1928\/m07ed11_sample.pdf. Accessed 10 Feb 2022."},{"key":"21435_CR42","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1476-0711-11-18","volume":"11","author":"K Konat\u00e9","year":"2012","unstructured":"Konat\u00e9, K. et al. Anti-bacterial activity against \u03b2-lactamase producing methicillin and ampicillin-resistants Staphylococcus aureus: Fractional inhibitory concentration index (FICI) determination. Ann. Clin. Microbiol. Antimicrob. 11, 18. https:\/\/doi.org\/10.1186\/1476-0711-11-18 (2012).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"21435_CR43","doi-asserted-by":"publisher","first-page":"e01760","DOI":"10.1128\/AAC.01760-18","volume":"63","author":"A Kavanagh","year":"2019","unstructured":"Kavanagh, A. Effects of microplate type and broth additives on microdilution MIC susceptibility assays. Antimicrob. Agents Ch. 63, e01760-e1818. https:\/\/doi.org\/10.1128\/AAC.01760-18 (2019).","journal-title":"Antimicrob. Agents Ch."},{"key":"21435_CR44","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jpha.2015.11.005","volume":"6","author":"M Balouiri","year":"2016","unstructured":"Balouiri, M., Sadiki, M. & Ibnsouda, K. S. Methods for in vitro evaluating antimicrobial activity. J. Pharm. Anal. 6, 71\u201379. https:\/\/doi.org\/10.1016\/j.jpha.2015.11.005 (2016).","journal-title":"J. Pharm. Anal."},{"key":"21435_CR45","doi-asserted-by":"publisher","first-page":"48","DOI":"10.22159\/ijpps.2019v11i3.28230","volume":"11","author":"D Thakur","year":"2019","unstructured":"Thakur, D. & Sahani, K. In vitro antimicrobial activity and MIC of the extracellular ethyl acetate crude extract of endophytic fungi Fusarium sp. isolated from Tephrosia purpurea root. Int. J. Pharm. Pharm. Sci. 11, 48\u201353 (2019).","journal-title":"Int. J. Pharm. Pharm. Sci."},{"key":"21435_CR46","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1128\/AAC.00056-13","volume":"57","author":"I Osaka","year":"2013","unstructured":"Osaka, I. & Hefty, P. S. Simple resazurin-based microplate assay for measuring chlamydia infections. Antimicrob. Agents Chem. 57, 2838\u20132840. https:\/\/doi.org\/10.1128\/AAC.00056-13 (2013).","journal-title":"Antimicrob. Agents Chem."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21435-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21435-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21435-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T02:07:38Z","timestamp":1665454058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-21435-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,10]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["21435"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-21435-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,10]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16988"}}